Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of Class A Ordinary Shares of Research Alliance Corp III as of September 30, 2026.

Key Highlights

  • Three reporting persons: Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai each report beneficial ownership of 822,500 Class A Ordinary Shares.
  • Ownership percentage: Each reporting person is reported as holding 9.0% of the outstanding Class A Ordinary Shares of Research Alliance Corp III.
  • Shares held directly: According to the filing, the 822,500 Ordinary Shares are held directly by Trails Edge Biotechnology Master Fund, LP.
  • Total shares outstanding: Ownership percentages are based on 9,098,529 Ordinary Shares issued and outstanding as of October 13, 2026, as reported in the issuer's Prospectus filed pursuant to Rule 424(b)(4) on November 4, 2026.
  • Event date: The date of the event requiring this filing is September 30, 2026.
  • Sole voting and dispositive power: Each reporting person reports sole voting power and sole dispositive power over 822,500 shares, with no shared voting or dispositive power.

Trails Edge Capital and Ortav Yehudai Disclose 9.0% Position as of September 30, 2026

According to the amended Schedule 13G filed on November 16, 2026, three related filers - Trails Edge Capital Partners, LP (a Delaware limited partnership), Trails Edge Biotechnology Master Fund, LP (a Cayman Islands limited partnership), and Ortav Yehudai - each report beneficial ownership of 822,500 Class A Ordinary Shares, $0.0001 par value per share, of Research Alliance Corp III. The filing identifies Research Alliance Corp III's principal offices as 600 Fifth Avenue, 23rd Floor, New York, NY 10020. The CUSIP number for the class of securities is G75226103.

The filing explains the relationships among the filers: Trails Edge Capital Partners, LP serves as the investment manager to Trails Edge Biotechnology Master Fund, LP, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital Partners, LLC. The filing states that Mr. Yehudai "exercises voting and investment discretion with respect to these securities" and therefore may be deemed to beneficially own 9.0% of the outstanding Ordinary Shares. All three filers share the same business address at 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326.

The filing certifies that, to the best of the filers' knowledge and belief, the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." This is Amendment No. 1 to an original Schedule 13G. A Joint Filing Agreement dated May 29, 2026, among the three filers is incorporated by reference as Exhibit 1.

What Was Disclosed

Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed an amended Schedule 13G disclosing beneficial ownership of 822,500 Class A Ordinary Shares of Research Alliance Corp III, representing 9.0% of the class, as of September 30, 2026.